Marinomed Biotech AGWBO:MARI -3.52%42 Days Payable is 310.25 as of Dec. 2025, which is 363% above its 10-year median of 66.96. GuruFocus rates WBO:MARI with a GF Score™ of 42/100 and a GF Value™ of €18.59 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 702 Biotechnology companies, Marinomed Biotech AG ranks better than 61.25% on this metric.
The historical rank and industry rank for Marinomed Biotech AG's Days Payable or its related term are showing as below:
WBO:MARI'
s Days Payable Range Over the Past 10 Years
Min: 46.9 Med: 66.96 Max: 236.95
Current: 182.16
During the past 11 years, Marinomed Biotech AG's highest Days Payable was 236.95. The lowest was 46.90. And the median was 66.96.
WBO:MARI's Days Payable is ranked better than 61.25% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs WBO:MARI: 182.16
Marinomed Biotech AG's Days Payable
increased
from Dec. 2024 (103.65) to Dec. 2025 (310.25).
It may suggest that Marinomed Biotech AGdelayed paying its suppliers.
Marinomed Biotech AG Days Payable Related Terms
Marinomed Biotech AG Days Payable Historical Data
* Premium members only.
The historical data trend for Marinomed Biotech AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:MARI vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Marinomed Biotech AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marinomed Biotech AG Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Marinomed Biotech AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Marinomed Biotech AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinomed Biotech AG (WBO:MARI) has a Days Payable of 310.25 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Marinomed Biotech AG and its competitors. This is 363% above median its historical median of 66.96. Over the past decade, Marinomed Biotech AG's Days Payable has ranged from 46.90 to 236.95. According to the industry distribution chart, Marinomed Biotech AG ranks #272 out of 702 companies in the Biotechnology industry, placing it in the top 38.7%.
Is Marinomed Biotech AG's Days Payable too high?
Marinomed Biotech AG's current Days Payable of 310.25 is 363% above median its 10-year median of 66.96. Over the past 10 years, this metric has ranged from a low of 46.90 to a high of 236.95. The Biotechnology industry median Days Payable is 113.56. Marinomed Biotech AG's value of 310.25 is 173.2% above this industry median. Based on the distribution chart, Marinomed Biotech AG ranks #272 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #272 out of 702 companies for Days Payable. This puts Marinomed Biotech AG in the upper half of its industry. The industry median Days Payable is 113.56. Marinomed Biotech AG's value of 310.25 is 173.2% above this benchmark. Historically, Marinomed Biotech AG's own Days Payable has ranged from 46.90 to 236.95 over the past decade. While the company's 10-year median is 66.96 vs. the industry median of 113.56, Marinomed Biotech AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marinomed Biotech AG's current Days Payable of 310.25 is 173.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Marinomed Biotech AG and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marinomed Biotech AG's current Days Payable is 310.25, which is 363% above median its own 10-year median of 66.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.59, compared to a current price of €9.60 — trading 48.4% below its estimated fair value. The current Days Payable is 310.25, which is 363% above median its 10-year median of 66.96 and 173.2% above the Biotechnology industry median of 113.56. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current Days Payable is 310.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?
Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued.
The current stock price of €9.60 is trading 48.4% below its estimated GF Value™ of €18.59.
GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.
Key valuation signals for WBO:MARI:
Days Payable: 310.25 (363% above median its 10-year median of 66.96)
GF Value™: €18.59 vs. price of €9.60 (48.4% below fair value)
Industry Position: 173.2% above the Biotechnology median (#272 of 702)
No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score
Get the complete analysis for WBO:MARI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:MARI has been successfully added to your 
